All In Biotech

NDA 020912 · Medicure

Aggrastat

Tirofiban Hydrochloride · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: May 16, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

May 14, 1998

Approved uses

2

Original approval plus efficacy supplements

Registered trials

69

25 Phase 3, 10 recruiting

FAERS reports

2,780

2,466 serious, 442 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 1, 2025.

AGGRASTAT® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). AGGRASTAT is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Mechanism: AGGRASTAT is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. When administered intravenously, AGGRASTAT inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the PRISM-PLUS regimen of 0.4 mcg/kg/min over 30 minutes followed by a 0.1 mcg/kg/min maintenance infusion, >90% inhibition of platelet aggregation is attained by the end of the 30-minute infusion. When given according to the recommended regimen of 25 mcg/kg followed by a 0.15 mcg/kg/min...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 10, 2013 Supplement 19 · Efficacy LabelLetter
  • May 14, 1998 Original approval · Type 1 - New Molecular Entity · priority review LetterLabel
2 products under this application
  • AGGRASTAT · TIROFIBAN HYDROCHLORIDE EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML) · SOLUTION, INJECTION · Prescription
  • AGGRASTAT · TIROFIBAN HYDROCHLORIDE EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML) · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Tirofiban" as an intervention, any sponsor and status, largest first.

All 69 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • haemorrhage376
  • thrombocytopenia295
  • myocardial infarction206
  • angina pectoris187
  • haemorrhage intracranial179
  • death146
  • cardiac failure acute118
  • cerebral haemorrhage110
  • acute respiratory failure99
  • cardiac failure88
  • vascular stent thrombosis80
  • infarction53

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200445
2005169
2006134
200759
200819
20097
201010
201111
201231
201315
201412
201514
201644
201774
201898
20191,159
2020236
2021137
2022305
202323
202466
202529
202683

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 441 on PubMed

Sponsor: Medicure

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.